Identifying risk factors for sudden cardiac arrest in coronary artery disease patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify clinical and genetic risk factors associated with sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in patients diagnosed with coronary artery disease (CAD). Participants will complete a survey regarding their medical history and socioeconomic status, undergo standard ECG recordings, and have physiological measurements taken. Blood samples will also be collected from a subset of participants for future genetic analysis. The study will utilize national death certificate data to track SCD cases and analyze the collected information to better understand risk factors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age \> 18 years
2. A patient who lives in the area of 'Wellbeing Services County of Pirkanmaa' and seeks treatment for coronary artery disease (CAD).
3. CAD is diagnosed with invasive coronary angiogram or computed tomography angiogram (CTA) which is evaluated by cardiologists based on current guidelines for stenosis level evaluation and fractional flow reserve (FFR) results.
4. An invasive coronary angiogram or CTA is done within three (3) months.
5. Good or moderate everyday functional ability

Exclusion Criteria:

1. Life expectancy \<1 months.
2. A significant valvular heart disease treated previously (endovascular or surgical) or requires treatment (endovascular or surgical) in the next three (3) months.
3. Previously implanted cardioverter-defibrillators (ICD) or will be implanted in the next three (3) months.
4. An active malignancy (ongoing treatment for a solid tumour, metastatic solid tumour, fast progressing haematological malignancy, or equal malignant disease).
5. A significant neurodegenerative disease (dementia, Mini-Mental State Examination (MMSE) \<23 or equivalenneurodegenerative disease affecting everyday functional ability, like ALS, myositis, prograded MS-disease or Parkinson's disease).
6. Intellectual disability or a significant disability affecting cognitive functions
7. Do-not-resuscitate (DNR) treatment decision

Subgroup with blood samples:

Blood samples are withdrawn from all study subjects under 76 years of age. Additionally, PaxGene samples are withdrawn from i) all study subjects under 65 years of age and ii) subjects between 65-76 years, if they have detected QRS-time\>110ms in the latest ECG.

Where it's running

• Tampere University Hospital Tampere Heart Centre
  Tampere, Pirkanmaa, Finland Recruiting

Study contacts

• Study coordinator: Jussi Hernesniemi, Professor
• Email: jussi.hernesniemi@tuni.fi

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting sudden cardiac arrest risk in people with coronary artery disease

  This project will try to see if combining genetics, ECGs, blood biomarkers, imaging, and psychosocial information can predict which people with coronary artery disease are most likely to have sudden cardiac arrest.

  Recruiting at 3 sites Tampere Heart Hospital · Hadera and 2 other locations · NCT07444931

• Genetic assessment of young athletes who experience sudden cardiac arrest during sports

  This study looks at young athletes aged 12 to 35 who have had sudden cardiac arrest during sports to see if genetic factors played a role and to help prevent similar events in others.

  Recruiting at 15 sites Rennes University Hospital · Nîmes, France and 25 other locations · NCT06642168

• Registry and biobank for arrhythmogenic ventricular cardiomyopathy

  This study is trying to gather information and samples from people with arrhythmogenic ventricular cardiomyopathy and their families to better understand the genetic causes of the condition and improve early diagnosis for those at risk.

  Recruiting at 2 sites Mayo Clinic · Rochester, Minnesota and 1 other locations · NCT03049254

• Red grape juice and metabolism in men with coronary disease

  Researchers will test whether daily red grape juice changes the blood metabolite profile in men with chronic coronary artery disease.

  Recruiting University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07777341

• Edoxaban vs. Apixaban in AF with CAD: Net Benefit

  This trial tests whether edoxaban-based therapy provides a similar or better overall benefit than apixaban-based therapy for stroke prevention and major bleeding in adults with atrial fibrillation and coronary artery disease.

  Recruiting Phase 4 Samsung Medical Center · Seoul · NCT07753200

• Revascularization of Calcified Coronary Arteries

  This study tests whether measuring blood flow and pressure before and after ballooning or stenting of calcified coronary arteries can help predict how well the procedure will work for adults with heart disease.

  Recruiting Aalborg University Hospital · Aalborg · NCT07724184

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.